Literature DB >> 23475700

High muscle sympathetic nerve activity is associated with left ventricular dysfunction in treated hypertensive patients.

Silvia Beatriz Cavasin de Souza1, Juraci Aparecida Rocha, Marco Antonio Romeu Cuoco, Grazia Maria Guerra, Julio Cesar Ferreira-Filho, Suellen Borile, Eduardo Moacyr Krieger, Luiz Aparecido Bortolotto, Fernanda Marciano Consolim-Colombo.   

Abstract

BACKGROUND: The presence of asymptomatic left ventricular diastolic dysfunction (LVDD) in hypertensive patients can be associated with the development of cardiac events. The increase in sympathetic activity may be 1 of the mechanisms that predisposes to this outcome. In this study, we analyzed 2 hypotheses: (i) whether sympathetic activity is higher in the presence of LVDD, independent of blood pressure control and (ii) whether different classes of LVDD have a different effect on sympathetic activity.
METHODS: After analyzing left ventricular function using echo Doppler cardiography, 45 hypertensive patients receiving treatment were allocated into 3 groups: normal function (LV-NF, n = 15), impaired relaxation (LV-IR, n = 15), and pseudonormal or restrictive (LV-P/R, n = 15). An age-, sex-, and body mass index-matched control group of normotensive volunteers (N, n = 14) was included. Muscle sympathetic nerve activity (MSNA), heart rate, and systolic blood pressure variabilities and baroreflex sensitivity were evaluated while the patient was in a supine position.
RESULTS: Blood pressure and antihypertensive drug use were similar among the hypertensive groups. The LV-IR and LV-P/R groups had similar MSNA (33±1 and 32±1 bursts/min, respectively), which was significantly higher than that of the LV-NF and N groups (26±3 and 15±2 bursts/min, respectively). The LV-IR and LV-P/R groups had significantly higher LF-systolic blood pressure variability and significantly lower baroreflex sensitivity compared with the N group.
CONCLUSIONS: The presence of asymptomatic LVDD is associated with increased MSNA, independent of blood pressure control. The sympathetic hyperactivity associated with LVDD is similar in the different patterns of LVDD studied.

Entities:  

Keywords:  blood pressure; diastolic dysfunction; hypertension; muscle sympathetic nerve activity.

Mesh:

Substances:

Year:  2013        PMID: 23475700     DOI: 10.1093/ajh/hpt032

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

Review 1.  Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases.

Authors:  Priya Balasubramanian; Delton Hall; Madhan Subramanian
Journal:  Geroscience       Date:  2018-12-05       Impact factor: 7.713

2.  Comparison of signal-averaging and regression approaches to analyzing sympathetic transduction.

Authors:  Myles W O'Brien; Beverly D Schwartz; Jennifer L Petterson; Derek S Kimmerly
Journal:  Clin Auton Res       Date:  2022-06-21       Impact factor: 5.625

Review 3.  The Role of Adipose Triglyceride Lipase and Cytosolic Lipolysis in Cardiac Function and Heart Failure.

Authors:  Ulrich Kintscher; Anna Foryst-Ludwig; Guenter Haemmerle; Rudolf Zechner
Journal:  Cell Rep Med       Date:  2020-03-25

Review 4.  The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?

Authors:  Marijana Tadic; Cesare Cuspidi; Athanasios Frydas; Guido Grassi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 5.  A systematic review concerning the relation between the sympathetic nervous system and heart failure with preserved left ventricular ejection fraction.

Authors:  Willemien L Verloop; Martine M A Beeftink; Bernadet T Santema; Michiel L Bots; Peter J Blankestijn; Maarten J Cramer; Pieter A Doevendans; Michiel Voskuil
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  Blood pressure categorization and subclinical left ventricular dysfunction in antihypertensive medication-naive subjects.

Authors:  Koki Nakanishi; Masao Daimon; Yuriko Yoshida; Jumpei Ishiwata; Naoko Sawada; Megumi Hirokawa; Hidehiro Kaneko; Tomoko Nakao; Yoshiko Mizuno; Hiroyuki Morita; Marco R Di Tullio; Shunichi Homma; Issei Komuro
Journal:  ESC Heart Fail       Date:  2022-02-24

7.  Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study.

Authors:  Kanokwan Bunsawat; Stephen M Ratchford; Jeremy K Alpenglow; Josef Stehlik; Adam S Smith; Russell S Richardson; D Walter Wray
Journal:  Auton Neurosci       Date:  2021-06-24       Impact factor: 2.355

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.